Addition Therapeutics unveiled its PRINT gene‑insertion platform after emerging from stealth with major backing and a plan to develop insertional gene therapies for chronic and rare disease. The UC Berkeley spinout said its RNA‑mediated insertion approach uses retrotransposase‑based machinery delivered in lipid nanoparticles and has drawn institutional investors and philanthropic support. The company shortly followed with a $106.5 million financing to advance preclinical development and scale its platform, a sum the firm says will underwrite IND‑enabling studies and manufacturing. Addition’s dual announcements underscore investor appetite for novel gene‑insertion strategies that aim to overcome delivery and integration challenges seen with conventional viral vectors.